

THE SYNTHESIS OF (3R)-NEROLIDOL


David E. Cane*, Hyun-Joon Ha, Douglas B. McIlwaine, and Keith O. Pascoc[§]

Department of Chemistry, Brown University, Providence, Rhode Island 02912;

[§]Department of Chemistry, University of the West Indies, Mona, Kingston 7, Jamaica

Summary: The sesquiterpene natural product (3R)-nerolidol has been prepared in six steps starting from (3R)-linalool.

Extensive experiments have established the intermediacy of the tertiary allylic esters, linalyl pyrophosphate and nerolidyl pyrophosphate (NPP) in the enzymatic formation of cyclic monoterpenes and sesquiterpenes from the respective acyclic precursors, geranyl and farnesyl pyrophosphate.¹ Based on these results we have proposed a comprehensive stereochemical scheme for terpenoid cyclizations which correlates the conformation and absolute configuration of linalyl and nerolidyl pyrophosphate with the configuration of the eventually formed monoterpene or sesquiterpene product.² For example, the enzymatic cyclization of farnesyl pyrophosphate to trichodiene has been shown to proceed exclusively by way of (3R)-NPP^{3a} while formation of β -*trans*-bergamotene is believed to involve the exclusive intermediacy of the corresponding (3S)-NPP.^{3b} Experimental testing of such proposals requires samples of the individual enantiomers of the relevant tertiary allylic pyrophosphate esters. Unfortunately, although both antipodes of linalool are readily available,⁴ only (3S)-nerolidol is conveniently obtained from natural sources.⁵ To overcome this difficulty, we have developed a short and efficient synthesis of (3R)-nerolidol (1) starting with the lower homolog (3R)-linalool (2).



Scheme 1

We have previously prepared samples of labeled farnesol, using the Julia coupling of allylic sulfones⁶ with derivatives of geranyl benzyl ether to effect construction of the farnesyl skeleton.⁷ The last step in this procedure involves the simultaneous removal of the phenylsulfonyl and benzyl residues by reductive elimination with Li/EtNH₂. Unfortunately, application of the analogous sequence to the corresponding benzyl ether of linalool

failed due to predominant cleavage of the allylic ether C-O bond during the reduction of the derived nerolidol benzyl ether. On the other hand, further experimentation revealed that the lithium salt of nerolidol itself was stable under the usual reducing conditions. We therefore turned to the use of the *t*-butyldimethylsilyl (TBDMS) protecting group. It was expected that the TBDMS group would be compatible with the functionalization and coupling of the linalool moiety, yet could be selectively removed prior to the eventual reductive cleavage of the phenylsulfonyl group. Accordingly, (3*R*)-linalool, 2, [α]²³D -13.5 (c 0.44, CHCl₃),⁴ was converted to the corresponding TBDMS ether 3 (1.2 equiv. TBDMSOTf, 2 equiv. 2,6-lutidine, CH₂Cl₂, rt, 30 min, 97 %).⁸ (Scheme 1) Oxidation of 3 with SeO₂ (0.5 equiv., EtOH, reflux, 4 h) followed by NaBH₄ reduction of the resulting mixture of aldehyde and alcohol gave the trans allylic alcohol 4 (23 %). Reaction of 4 with triphenylphosphine (2 equiv.) in refluxing carbon tetrachloride⁹ (4 h) afforded the allylic chloride 5 (48 %) which was coupled (THF, -78 °C, 0.5 h) with the sulfonyl-stabilized anion generated by treatment of dimethylallyl phenyl sulfone (6) (1.2 equiv) with *n*-butyl lithium (1.1 equiv, -78 °C, 0.5 h and rt, 0.5 h) to produce the (3*R*)-9-phenylsulfonyl nerolidol TBDMS ether (7) in 78 % purified yield. Deprotection with (*n*-Bu)₄NF (2 equiv) in refluxing THF (18 h) gave 9-phenylsulfonyl nerolidol (8) (82 %, mp 93-94 °C). Finally, reaction of 8 with 2 equiv of *n*-BuLi in THF generated the corresponding lithio alkoxide which underwent smooth reductive elimination of the phenylsulfonyl group by treatment with excess Li in EtNH₂ (-78 °C, 20 min) to afford, after chromatographic purification, a 72 % yield of (3*R*)-nerolidol (5), [α]²³D -12.5 (c 0.022, CHCl₃).⁵

Acknowledgement: This work was supported by a grant from the National Institutes of Health, GM 30301. We would like to thank Firmenich, S.A. of Geneva, Switzerland for a generous gift of (3*R*)-linalool.

References and Notes

1. Croteau, R. *Chem. Rev.* **1987**, *87*, 929; Cane, D. E. *Chem. Rev.* **1990**, *90*, in press.
2. Cane, D. E. *Acc. Chem. Res.* **1985**, *18*, 220.
3. a) Cane, D. E.; H.-J. Ha *J. Am. Chem. Soc.* **1988**, *110*, 6865. b) Cane, D. E.; McIlwaine, D. B.; Harrison, P. H. M. *J. Am. Chem. Soc.* **1989**, *111*, 1152.; Cane, D. E.; McIlwaine, D. B.; Oliver, J. S. *J. Am. Chem. Soc.* **1990**, *112*, 1285.
4. Cf. Satterwhite, D. M.; Wheeler, C. J.; Croteau, R. *J. Biol. Chem.* **1985**, *260*, 13901.
5. Vlad, P.; Soucek, M. *Collect. Czech. Chem. Commun.* **1962**, *27*, 1726.
6. Julia, M.; Ward, P. *Bull. Soc. Chim. Fr.* **1973**, *11*, 3065.
7. Cane, D. E.; Abell, C.; Tillman, A. M. *Bioorg. Chem.* **1984**, *12*, 312.
8. All new compounds exhibited spectroscopic data (¹H and ¹³C NMR, ir, and ms) consistent with the assigned structure and gave satisfactory elemental analysis or high resolution ms data. 3: ¹H NMR (CDCl₃): 5.84 (1H, dd, J = 10.7, 17 Hz), 5.38 (1H, m), 5.14 (1H, dd, J = 1.6, 17.3 Hz), 4.99 (1H, dd, J = 1.6, 10.7 Hz), 3.98 (2H, s), 2.05 (2H, m), 1.65 (3H, s), 1.47 - 1.52 (2H, m), 1.30 (3H, s), 0.87 - 0.90 (9H, m), 0.05 - 0.08 (6H, m). 7: ¹H NMR (CDCl₃): 7.81 (2H, m), 7.59 (1H, m), 7.51 (2H, m), 5.86 (1H, ddd, J = 2, 10.7, 17.3 Hz), 5.17 (2H, m), 5.03 (1H, dt, J = 1.08, 10.7 Hz), 4.87 (1H, dd, J = 1.2, 10.7 Hz), 3.85 (1H, dddd, J = 2.7, 3.06, 3.10, 10.7 Hz), 2.83 (1H, bd, J = 13 Hz), 2.27 (1H, dd, J = 2.6, 12.3 Hz), 1.97 (2H, m), 1.63 (3H, m), 1.48 (5H, m), 1.24 (3H, d, J = 2.7 Hz), 1.14 (3H, s). 1: ¹H NMR (CDCl₃): 5.9 (1H, dd, J = 10.7, 17 Hz), 5.18 - 5.23 (1H, dd, J = 1.3, 17 Hz), 5.04 - 5.16 (3H, m), 1.95 - 2.07 (6H, m), 1.53 - 1.67 (11H, m), 1.28 (3H, s).
9. Franzus, B.; Huang, T. T.-S.; Slagle, J. D. *J. Org. Chem.* **1981**, *46*, 3526.

(Received in USA 19 October 1990)